Author

B. Meibohm

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Organism:C. elegans· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

G. T. Robertson· 2 shared J. Liu· 2 shared M. Gonzalez-Juarrero· 2 shared A. A. Bauman· 1 shared A. Cullom· 1 shared A. J. Hickey· 1 shared A. J. Lenaerts· 1 shared A. MacNeil· 1 shared

Activity by Year

2023-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

G. T. Robertson

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer

D. Oluwalana, K. L. Adeleye, R. I. Krutilina, H. Chen, H. Playa, S. Deng, D. N. Parke, J. Abernathy, L. Middleton, A. Cullom, B. Thalluri, D. Ma, B. Meibohm, D. D. Miller, T. N. Seagroves, W. Li

This study evaluates the biological activity of 60c, a next-generation colchicine-binding site inhibitor, showing improved potency and anti-metastatic effects in triple-negative breast cancer models.

bioRxiv · May 22, 2024Cancer Biology

Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis

A. A. Bauman, J. P. Sarathy, F. Kaya, L. M. Massoudi, M. S. Scherman, C. Hastings, J. Liu, M. Xie, E. J. Brooks, M. E. Ramey, I. L. Jones, N. D. Benedict, M. R. Maclaughlin, J. A. Miller-Dawson, S. L. Waidyarachchi, , G. T. Robertson

This study shows that MBX-4888A, a spectinamide, shortens tuberculosis treatment in murine models by improving tissue distribution and working well with rifampin and pyrazinamide.

bioRxiv · May 13, 2024Microbiology

The atypical antipsychotic aripiprazole alters the outcome of disseminated Candida albicans infections.

P. Reitler, J. Regan, C. DeJarnette, A. Srivastava, J. A. Carnahan, K. M. Tucker, B. Meibohm, B. M. Peters, G. E. Palmer

This study shows that aripiprazole, an atypical antipsychotic, worsens outcomes of disseminated Candida albicans infections in mice but has minimal effects on fungal growth or gene expression.

bioRxiv · Feb 13, 2024 · PreprintMicrobiology

A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides

M. Zohaib Ali, T. S. Dutt, A. MacNeil, A. Walz, J. Patterson, C. Pearce, H. Lam, J. S. Philp, R. Lee, J. Liu, G. T. Robertson, A. J. Hickey, B. Meibohm, M. Gonzalez-Juarrero

This paper evaluates a modified BPaL regimen replacing linezolid with inhaled spectinamide 1599 for tuberculosis treatment, showing similar efficacy while avoiding linezolid-associated adverse events.

bioRxiv · Nov 16, 2023Microbiology